company background image
REC logo

Recordati Industria Chimica e Farmaceutica BIT:REC Stock Report

Last Price

€46.64

Market Cap

€9.6b

7D

-7.9%

1Y

-5.6%

Updated

13 Apr, 2025

Data

Company Financials +

Recordati Industria Chimica e Farmaceutica S.p.A.

BIT:REC Stock Report

Market Cap: €9.6b

REC Stock Overview

Researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. More details

REC fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance3/6
Financial Health3/6
Dividends4/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Recordati Industria Chimica e Farmaceutica S.p.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Recordati Industria Chimica e Farmaceutica
Historical stock prices
Current Share Price€46.64
52 Week High€60.95
52 Week Low€43.98
Beta0.54
1 Month Change-11.50%
3 Month Change-11.33%
1 Year Change-5.63%
3 Year Change-3.22%
5 Year Change21.68%
Change since IPO3,489.90%

Recent News & Updates

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.67

Mar 22
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.67

Is Now The Time To Put Recordati Industria Chimica e Farmaceutica (BIT:REC) On Your Watchlist?

Mar 19
Is Now The Time To Put Recordati Industria Chimica e Farmaceutica (BIT:REC) On Your Watchlist?

Recent updates

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.67

Mar 22
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.67

Is Now The Time To Put Recordati Industria Chimica e Farmaceutica (BIT:REC) On Your Watchlist?

Mar 19
Is Now The Time To Put Recordati Industria Chimica e Farmaceutica (BIT:REC) On Your Watchlist?

Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Jan 05
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Do Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings Warrant Your Attention?

Dec 18
Do Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings Warrant Your Attention?
author-image

Calculated Acquisitions And Market Expansions Set The Stage For Robust Financial Growth

Nov 18 Strategic acquisitions and market expansions enhance revenue growth, especially the rights to Enjaymo and early Isturisa approval in China.

We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings

Nov 18
We Like The Quality Of Recordati Industria Chimica e Farmaceutica's (BIT:REC) Earnings

Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60

Nov 14
Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Due To Pay A Dividend Of €0.60

Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 13
Earnings Beat: Recordati Industria Chimica e Farmaceutica S.p.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar

Oct 31
Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Not Flying Under The Radar

Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Sep 07
Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt

Aug 20
We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt

Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts

Aug 02
Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 31% And Analysts Are Revising Their Forecasts

Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price

Aug 01
Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Business Is Yet to Catch Up With Its Share Price

Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

May 26
Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)

Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63

May 10
Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63

Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63

Apr 25
Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63

Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk

Apr 23
Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk

Shareholder Returns

RECIT PharmaceuticalsIT Market
7D-7.9%-5.6%-2.0%
1Y-5.6%-19.6%0.6%

Return vs Industry: REC exceeded the Italian Pharmaceuticals industry which returned -19.6% over the past year.

Return vs Market: REC underperformed the Italian Market which returned 0.6% over the past year.

Price Volatility

Is REC's price volatile compared to industry and market?
REC volatility
REC Average Weekly Movement4.4%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement5.1%
10% most volatile stocks in IT Market8.2%
10% least volatile stocks in IT Market3.2%

Stable Share Price: REC has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: REC's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19264,539Rob Koremansrecordati.com

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in maple syrup urine diseases; Isturia for endogenous Cushing’s syndrome; Cystadrops for corneal cystine crystal deposits; Carbaglu for hyperammonemia due to n-acetyl glutamate synthase deficiency; Qarziba for neuroblastoma patients and patients with relapsed or refractory neuroblastoma; and Fortivda for renal cell carcinoma.

Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary

How do Recordati Industria Chimica e Farmaceutica's earnings and revenue compare to its market cap?
REC fundamental statistics
Market cap€9.62b
Earnings (TTM)€416.51m
Revenue (TTM)€2.34b

23.1x

P/E Ratio

4.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
REC income statement (TTM)
Revenue€2.34b
Cost of Revenue€703.78m
Gross Profit€1.64b
Other Expenses€1.22b
Earnings€416.51m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

May 08, 2025

Earnings per share (EPS)2.02
Gross Margin69.94%
Net Profit Margin17.79%
Debt/Equity Ratio130.1%

How did REC perform over the long term?

See historical performance and comparison

Dividends

2.7%

Current Dividend Yield

63%

Payout Ratio

Does REC pay a reliable dividends?

See REC dividend history and benchmarks
When do you need to buy REC by to receive an upcoming dividend?
Recordati Industria Chimica e Farmaceutica dividend dates
Ex Dividend DateMay 19 2025
Dividend Pay DateMay 21 2025
Days until Ex dividend36 days
Days until Dividend pay date38 days

Does REC pay a reliable dividends?

See REC dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/13 08:48
End of Day Share Price 2025/04/11 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 24 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paola SagliettiBanca Akros S.p.A. (ESN)
Charles PitmanBarclays
Nicolas Guyon-GellinBNP Paribas Exane